drugset / Trial / NCT07634484
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2027-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | K-877 | Unknown | 0.2 mg | Oral |
| Subject | K-877 | Unknown | 0.4 mg | Oral |